Brandon White
@bwhite5290
Co-founder of Axiom, Best Seven Foot ML Engineer in the World
Announcing Axiom: Eliminating drug toxicity, without using animals! Alex Beatson and I founded Axiom a little over over a year ago with the mission of eliminating drug toxicity by replacing traditional experiments, such as animal testing, with AI models. We are excited to…
San Francisco just got a proposal for the tallest tower on the West Coast. And this is not just about one building. This plan would transform a vacant city block into a dynamic mix of housing, office space, retail, and public space by developing the former PG&E and Matson…
BREAKING: Proposed S.F. tower would be 15 stories taller than Salesforce and forever change the city skyline. sfchronicle.com/sf/article/new…
ashlee & the @corememory team are among the best storytellers in science. we were privileged to host them for a look inside @newlimit. we hope this is only the first of many windows into our mission to add healthy years to each life.
Our new @corememory video on @newlimit, which is finding combinations of proteins that reverse aging across the body. It is perhaps the most exciting work in the bio-tech field. Backed by @brian_armstrong @patrickc @collision @JoshuaKushner @natfriedman and others
Excited to share our first public profile in a decade - joining Ramtin to help build Abstract 2.5 years ago was the best career decision I could've made. And we're just getting started, hope you enjoy the article!
Ramtin Naimi started a successful hedge fund at 19, went bankrupt at 24, and then built a $1.8 billion venture firm backed by investing icons like Stanley Druckenmiller, @pmarca, and @BillAckman. Michael Ovitz calls Naimi his “non-biological son.” Founders say he’s “the most…
Incredible profile on my friend @ramtinnaimi in @joincolossus Ramtin's drive and work ethic have inspired me for years and I'm glad he's finally telling his story publicly. Undoubtedly a future Hall of Famer
Ramtin Naimi started a successful hedge fund at 19, went bankrupt at 24, and then built a $1.8 billion venture firm backed by investing icons like Stanley Druckenmiller, @pmarca, and @BillAckman. Michael Ovitz calls Naimi his “non-biological son.” Founders say he’s “the most…
We’ve been quietly building Abstract for 9 years. Thank you to @patrick_oshag and @domcooke @joincolossus for giving us the opportunity to share our story. We’re just getting started! joincolossus.com/article/ramtin…
GUYS STOP USING EXPENSIVE AS A DISQUALIFIER. capability per dollar will drop 100x/year. “$3k task ARC-AGI 80%” could prob be $30 if we cared to optimize it. repeat after me: all that matters is top line intelligence. all that matters is top line intelligence…
All the tech bros this morning thinking that AGI has been achieved because some (insanely expensive) new form of LLMs can now match top *high school students* on one specific task … it’s almost … cute! ☺️
There were multiple times since Kalshi was founded in late 2018 when Luana and I contemplated giving up. Going up against the federal government can sometimes feel like an impossible task. But thanks to our incredible team, we successfully defeated the bureaucracy and are now…
We’re about to leave San Francisco and return to Paris. We’ve been deeply moved by the optimism of the people here. Every time we spoke about our grand dream, we were never met with skepticism—only encouragement, and offers to help make it real. We came here to seek funding for…
The last two months have been insane. I randomly came into the office this morning and decided to record this video on why there has literally never been a more exciting time to join @sievedata. We're working with leading research teams pushing the frontier of creative, robotics,…
The @NIH announcement of no “animal model only” grants is arguably a bigger deal than the pending 40% budget cut. The question is what it really means. e.g., mice + AI = “not pure animal model” grant etc. @NIHDirector_Jay @NIH @HHSGov please clarify. I’m getting Qs galore.
Dimension portco @MonteRosaTx casually on the cover of Science 🚀
New research in Science greatly expands the potential target scope of molecular glues and should stimulate the development of new small molecules that can selectively target therapeutically relevant proteins for degradation. Learn more in this week's issue:…
We’re excited to introduce Chai-2, a major breakthrough in molecular design. Chai-2 enables zero-shot antibody discovery in a 24-well plate, exceeding previous SOTA by >100x. Thread👇
Learn how to find cracked people from Iowa, Ohio, Pittsburgh, Atlanta, North Carolina, Wisconsin/Minnesota, and Nebraska. They are so good and waiting for an opportunity to unleash limitless potential.
Data is the oil of modern biotech. New tools allow us to model living systems too complex for unaided human cognition. Latch is releasing a new capabilities in data curation + delivery: - 30M observational cell atlas across 150 diseases, 200 tissues, 27 technologies - a…
Interesting options to build the ScaleAI of bio: 1) Given a set of tier 1 and tier 2 data for a molecule and a set of follow-up experimental options, decide what to do next - explain your reasoning. (This data can be curated from patents/literature, generated in lab at scale, or…
If you're building the Scale AI for biological data (or, frankly, any kind of scientific data) to enable reasoning models, please reach out! I want to help you make it happen
We've grown a lot despite historically grim market conditions in biotech and the reason for this is interesting. Adoption of new data generation methods across industry still fragmented so we now work directly with the companies that build + sell them.
Another gene therapy death BTW. This one out of China reported in NEJM. Safety is biggest issue with gene therapies and all new therapeutic modalities. Would patients tolerate this many deaths with small molecules? Antibodies? RNAi? So far looks like IV AAV gene therapies are…